(Q33415354)

English

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

Giorgio Inghirami

6

object named as

Giorgio Inghirami

0 references

Annalisa Chiappella

object named as

Annalisa Chiappella

2

0 references

object named as

Ileana Baldi

5

0 references

object named as

Marco Ladetto

9

0 references

object named as

Michele Spina

7

0 references

Giovannino Ciccone

object named as

Giovannino Ciccone

22

0 references

object named as

Umberto Vitolo

1

0 references

object named as

Giuseppe Rossi

24

0 references

Gianluca Gaidano

23

object named as

Gianluca Gaidano

2 references

Europe PubMed Central

PubMed publication ID

26 July 2017

ORCID Public Data File 2021

Anna Marina Liberati

10

object named as

Anna Marina Liberati

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

13

object named as

Flavia Salvi

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Martin Dreyling

16

object named as

Martin Dreyling

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Silvia Franceschetti

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Angelo Michele Carella

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Giorgio Inghirami

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Vincenzo Pavone

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anna Lia Molinari

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pierluigi Zinzani

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pier Paolo Fattori

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alfonso Zaccaria

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Barbara Botto

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alessia Castellino

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Angela Congiu

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Marcello Gaudiano

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Manuela Zanni

21

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Fondazione Italiana Linfomi

25

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

13 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

730-737

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Stromal gene signatures in large-B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970191-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70191-3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33415354&oldid=2095825943"